ALDX
Aldeyra TheNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$93.50M
P/E Ratio
—
EPS
$-0.45
Beta
1.15
52W High
$6.17
52W Low
$1.07
50-Day MA
$1.78
200-Day MA
$4.32
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-28.13M |
| Operating Margin | 0.00% |
| Return on Equity | -51.80% |
| Return on Assets | -22.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.70 |
| Price-to-Book | 2.22 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 6.96 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $60.32M |
| Float | $52.88M |
| % Insiders | 3.18% |
| % Institutions | 62.76% |
Analyst Ratings
Consensus ($7.60 target)
1
Strong Buy3
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026